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OBJECTIVES The diagnostic importance of circulating solubilized tumor necrosis factor-alpha receptor II
(sTNF-aRII) and interleukin-2 receptor in coronary heart disease (CHD) was evaluated. In
addition, these variables were correlated with solubilized adhesion molecule levels (i.e.,
intracellular adhesion molecule [ICAM], vascular cell adhesion molecule [VCAM], and
E-selectin).
BACKGROUND Atherosclerosis is considered to be a chronic inflammatory process. Because the immunologic
network presents an abundance of positive and negative feedback mechanisms, information
obtained from different immunologic variables might be highly redundant.
METHODS In a cross-sectional study design, 60 patients with angiographically proven CHD were
compared with 60 individuals who had undergone coronary angiography but in whom no
evidence of stenosis could be found (control subjects). Angiography was performed at least
one year before the study. Cytokine levels were determined by enzyme-linked immunosorbent
assay technique and evaluated by univariate and multivariate statistical methods.
RESULTS All immunologic variables except E-selectin (p 5 0.08) significantly discriminated between
patients and control subjects. Coronary artery bypass graft surgery after angiography did not
lead to significant differences in the variables investigated in the patients with bypass surgery
as compared with the subjects without bypass surgery. Receiver-operating characteristics
analysis showed comparable test accuracy for solubilized adhesion molecules and cytokine
receptors. Multivariate logistic regression analysis, including age, revealed that only ICAM
and sTNF-aRII were independently correlated with the presence of CHD. Patients
belonging to the third tertile of at least one of these two variables demonstrated a 1.6- to
2-fold increased relative risk for the presence of CHD.
CONCLUSIONS We concluded that both circulating ICAM and TNF-aRII should be further evaluated as
markers for atherosclerotic changes in the coronary system. (J Am Coll Cardiol 1999;34:
1995–2001) © 1999 by the American College of Cardiology
Atherosclerosis can be described as a chronic inflammatory
process (1). During recent years there has been growing
interest in the evaluation of suitable markers of inflamma-
tion, which might be associated with atherogenesis. Because
the adhesion of monocytes to the endothelium through
adhesion molecules such as vascular cell adhesion molecule
(VCAM), intracellular adhesion molecule (ICAM) and
E-selectin is an early event in atherogenesis, these markers
are of particular interest. Many studies have reported a
relation between these adhesion molecules and acute or
chronic atherosclerotic vascular disease (2–4). All of these
variables are rapidly synthesized in response to cytokines (5).
However, most of these cytokines appear only transiently in
blood and have a short half-life. Circulating cytokine
receptors, which are released after contact with the corre-
sponding cytokine, also show basal serum levels in healthy
subjects. Because their serum concentrations correlate with
the cellular response to cytokines, circulating cytokine re-
ceptors might also provide additional information in chronic
inflammatory processes such as atherosclerosis. In this study
we evaluated the importance of solubilized tumor necrosis
factor-alpha receptor II (sTNF-aRII) (p75) as an indirect
marker of monocyte/macrophage stimulation and solubi-
lized interleukin-2 (IL-2) receptor (CD25) as a marker for
T-lymphocyte activation in patients with coronary heart
disease (CHD). In addition, we analyzed circulating adhe-
sion molecules (VCAM, ICAM and E-selectin) and corre-
lated all immunologic variables in a multivariate model to
evaluate whether additional information can be obtained by
cytokine receptor levels or whether the measurement of
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these variables provides only redundant information con-
cerning the presence of an inflammatory state of atheroscle-
rosis.
METHODS
Subjects. All subjects included in this study were suspected
of having CHD. As a consequence, these patients had to
undergo coronary angiography at our hospital. To obtain a
sufficient amount of patients and control subjects, 805
consecutive records of patients with coronary angiography
performed at least one year but no longer than two years
before recruitment were reviewed. Information on angio-
graphic findings like degree and localization of a stenosis of
the coronary arteries was obtained from standardized report
forms, which had to be filled out by an experienced
cardiologist directly after evaluation of the angiographic
study. All procedures were performed according to the
recommendations of quality management in the heart cath-
eterization laboratory (6). The proportion of angiographic
studies without significant pathologic findings ranged be-
tween 10% and 15% during the last two years, which is in
accordance with performance statistics of heart catheteriza-
tion laboratories in Germany (7).
A subject was considered as a control if no stenosis of the
coronary arteries was reported. In addition, no clinical
evidence such as alterations in the electrocardiogram were
apparent since angiography. Patients with CHD were
defined as those individuals exhibiting a significant stenosis
of .50% of at least one main branch of the coronary
arteries. Patients with myocardial infarction or unstable
angina within the last three months were excluded from
further study. Furthermore, none of the patients with CHD
had a history of coronary artery bypass graft surgery
(CABG) or percutaneous transluminal coronary angioplasty
within the last year.
The subjects examined were invited by phone for an
informal visit to the hospital regarding the aims of the study.
The recruitment of participants was continued until a
balanced distribution of 30 men and 30 women in both the
patient and the control group was reached. All of the 60
patients and 60 control subjects gave written consent in
compliance with the local Human Studies Committee and
were included in the study between December 1996 and
October 1997. Age ranged from 35 to 78 years in the
control group and from 42 to 76 years in the CHD group.
Of the 60 patients with CHD, 28 (47%, 14 men and 14
women) had a history of CABG .1 year before recruit-
ment. Subjects with acute or chronic inflammatory diseases,
current smokers, subjects with malignancies, renal, hepatic
or thyroid diseases or diabetes mellitus or those treated with
immunosuppressive or cytotoxic drugs were excluded.
Blood sampling and laboratory determinations. Blood
was drawn in the sitting position from the antecubital vein
between 8:00 and 9:00 AM in the fasting state. All medica-
tions were withdrawn for at least 12 h. The blood samples
were immediately cooled on ice. Serum was obtained by
subsequent centrifugation at 3,000g for 10 min. All samples
were stored at 270°C until assayed.
Total cholesterol and triglyceride levels were measured
enzymatically by the CHOD-PAP and GPO-PAP meth-
ods (Boehringer Mannheim, Germany). Low density li-
poprotein and high density lipoprotein cholesterol levels
were determined as recommended by the guidelines of the
Lipid Research Clinics Program (8). C-reactive protein
(CRP) was measured by nephelometry (Boehringer Mann-
heim, Mannheim, Germany). Leukocyte count was per-
formed using a CellDyne 3000 auto-analyzer (Abbott,
Wiesbaden, Germany). Serum levels of solubilized adhesion
molecules (VCAM, ICAM and E-selectin) and solubilized
cytokine receptors (TNF-aRII and IL-2 receptor) were
determined by commercially available enzyme-linked im-
mosorbent assay (DPC Biermann, Bad Nauheim, Germa-
ny).
Statistics. The Statistical Package for the Social Science
(SPSS for Windows 6.01) was employed for statistical
analysis. Variables were tested by the Mann-Whitney U test
to analyze differences of the distribution between the two
groups. Differences in prevalence were tested by the non-
parametric chi-square test. Multiple linear regression anal-
ysis and multiple logistic regression analysis were performed
to evaluate the independent effects of the distinct immuno-
logic variables investigated with respect to CHD. Receiver-
operating characteristics (ROC) analysis was performed
according to Beck and Shultz (9) to estimate the potential of
the variables tested to discriminate between patients with
CHD and control subjects (10). All analyses were tested
two-sided and p values ,0.05 were considered statistically
significant.
RESULTS
Subject profile. Table 1 presents the clinical characteristics
of the subjects investigated. Patients and control subjects
differed in their age distribution with significantly higher
Abbreviations and Acronyms
AUC 5 area under the curve
CABG 5 coronary artery bypass graft surgery
CHD 5 coronary heart disease
CRP 5 C-reactive protein
HMG-CoA 5 hepatic hydroxymethyl glutaryl
coenzyme A
(s)ICAM 5 (solubilized) intracellular adhesion
molecule
IL-2 5 interleukin-2
ROC 5 receiver-operating characteristics
(s)TNF-aRII 5 (solubilized) tumor necrosis factor-
alpha receptor II
(s)VCAM 5 (solubilized) vascular cell adhesion
molecule
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median values in the patient group (65 vs. 62 years). Fifty
(83%) of the investigated 60 patients with CHD had a
history of past myocardial infarction. Patients with one-
vessel disease (n 5 28) slightly prevailed over patients with
two- or three-vessel disease (n 5 16 each). There was a
subset of patients with a reduced ejection fraction (,60%);
however, no significant differences in prevalence were obvi-
ous between patients and control subjects.
Anthropometric variables (body mass index, waist to hip
ratio) and systolic and diastolic blood pressure were com-
parable between the groups. Lipid profiles were similar in
patients and control subjects. However, there was a signif-
icantly higher prevalence of subjects receiving lipid-lowering
drugs in the CHD group (48% vs. 8%). In contrast, use of
diuretic agents and beta-blocker did not differ significantly
between the subgroups investigated. Smoking habits were
also comparable with respect to the prevalence of former
smokers, because current smokers were not included in this
study.
White blood cell counts were within the reference range
(,10 cells/nl) in all subjects investigated and did not differ
statistically between patients and control subjects. In paral-
lel, CRP levels were also comparable between the sub-
groups. Three subjects in the CHD group and two subjects
in the control group exhibited slightly elevated CRP levels
(10 to 20 mg/l) without any obvious clinical correlate.
Univariate analysis of serum levels of solubilized adhe-
sion molecules and cytokine receptors. As shown in
Table 2, significant differences in plasma levels were ob-
served for solubilized VCAM, ICAM, TNF-aRII and IL-2
receptor, with higher median values in the CHD group.
Solubilized E-selectin did not reach the level of significance
(p 5 0.086), even though median values were 30% (63 vs.
48 ng/ml) higher in patients with CHD as compared with
control subjects. However, there was a wide overlap between
the two groups. As shown in Figure 1, control subjects with
a reduced ejection fraction tended to have higher adhesion
molecule and cytokine receptor levels, which in fact reduced
the median differences between patients and control sub-
jects. Interestingly, vessel disease without former myocardial
infarction was also accompanied by elevated adhesion mol-
ecule and cytokine receptor levels (with the exception of
solubilized ICAM).
There were also no significant gender-specific differences
in adhesion molecule and cytokine receptor levels (data not
shown). Solubilized TNF-aRII and IL-2 receptor levels
significantly correlated with age (p , 0.01), even though the
resulting correlation coefficients of linear regression analysis
were only 0.266 and 0.296, respectively.
Previous CABG in patients with CHD (n 5 28) did not
result in significant differences in the distribution of all
immunologic variables investigated in comparison to pa-
Table 1. Characteristics of Patients With Coronary Heart Disease and Control Subjects
CHD Group
(n 5 60)
Control Group
(n 5 60) p Value
Male/female ratio 30/30 30/30 1.000
Age (yrs) 65 (47–75) 62 (39–76) 0.040
Body mass index (kg/m2) 27.5 (22–34) 27.3 (23–34) 0.954
Waist/hip ratio 0.90 (0.80–0.98) 0.89 (0.80–0.97) 0.370
Systolic blood pressure (mm Hg) 150 (120–195) 140 (115–200) 0.205
Diastolic blood pressure (mm Hg) 87 (70–107) 85 (70–108) 0.657
Leukocytes (nl21) 6.3 (3.4–9.7) 5.6 (2.2–9.3) 0.147
C-reactive protein (mg/liter) 4.5 (0.9–18.5) 4.2 (0.5–11.5) 0.384
Total cholesterol (mmol/liter) 6.3 (4.6–9.9) 6.5 (4.9–9.1) 0.333
Triglycerides (mmol/liter) 1.9 (0.9–6.2) 1.6 (0.8–5.4) 0.182
LDL cholesterol (mmol/liter) 4.1 (2.4–6.6) 4.6 (3.0–6.7) 0.097
HDL cholesterol (mmol/liter) 1.4 (0.8–2.1) 1.3 (0.8–2.1) 0.564
Lipid lowering drugs 29 (48%) 5 (8%) , 0.001
Beta-blocker 25 (42%) 19 (32%) 0.273
ACE inhibitors 32 (53%) 22 (37%) 0.076
Diuretic drugs 15 (25%) 15 (25%) 0.890
Ex-smokers 26 (43%) 23 (38%) 0.590
History of myocardial infarction 50 (83%) 0 —
Ejection fraction
.60% 45 (75.0%) 49 (81.7%) 0.360*
60–40% 14 (23.3%) 10 (16.7%) —
39–20% 1 (1.7%) 1 (1.7%) —
,20% 0 0 —
*Ejection fractions .60% and 60% to 40% were compared between patients and control subjects by the nonparametric chi-square test. Data are presented as the median value
with 5th to 95th percentile in parentheses or as number (%) of patients.
ACE 5 angiotensin-converting enzyme; CHD 5 coronary heart disease; HDL and LDL 5 high and low density lipoprotein, respectively.
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tients with CHD without CABG (data not shown). The
use of lipid-lowering drugs, beta-blockers, angiotensin-
converting enzyme inhibitors or diuretic agents also had no
obvious effect on the results obtained.
The ROC analysis was performed to provide an index for
assessment of the accuracy of the variables investigated to
discriminate between subjects with angiographically proven
CHD and those without it. The cutoff values and the areas
under the curve (AUC) are given in Table 3. The AUC
represents the probability that a randomly chosen patient
with disease is correctly rated or ranked with greater
suspicion than a randomly chosen subject without disease.
There were no obvious differences in AUC values between
the variables listed, which ranged from 0.557 (sVCAM) to
0.606 (sTNF-aRII). The discriminative power of age was
comparable to the immunologic variables (AUC 5 0.605).
Logistic regression analysis. To assess the independent
interrelation between the immunologic variables investi-
gated and CHD, multivariate logistic regression analysis
was performed, including age in the model as another
covariate with statistical significance in univariate analysis.
The power of the multiple logistic regression model used
was calculated as 99.7%. The estimation of model discrim-
Figure 1. Serum levels of adhesion molecules and cytokine receptors in control subjects (2/2), control subjects with heart failure (HF)
(i.e., ejection fraction ,60%), patients with coronary heart disease (CHD), with former myocardial infarction (MI), and patients with
CHD with diseased vessels (VD) but no history of myocardial infarction. Bars indicate median values.
Table 2. Comparison of Solubilized Adhesion Molecules and Cytokine Receptors Between Patients With Coronary Heart Disease
and Control Subjects
CHD Group
(n 5 60)
Control Group
(n 5 60) p Value
sIL-2 receptor (U/ml) 415 (193–722) 325 (178–759) 0.041
sTNF-aRII (pg/ml) 3,516 (2,323–5,981) 3,217 (1,964–4,199) 0.016
sVCAM (ng/ml) 668 (495–1,232) 616 (455–1,133) 0.020
sICAM (ng/ml) 165 (100–397) 149 (100–228) 0.026
sE-selectin (ng/ml) 63 (19–125) 48 (20–108) 0.086
Data are presented as the median value with 5th to 95th percentile in parentheses.
CHD 5 coronary heart disease; sICAM 5 solubilized intracellular adhesion molecule; sIL-2 5 solubilized interleukin-2; sTNF-aRII 5 solubilized tumor necrosis
factor-alpha receptor II; sVCAM 5 solubilized vascular cell adhesion molecule.
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ination as a means to evaluate the model performance
showed that 68% of all subjects were correctly classified.
The goodness-of-fit of this model, as quantified by the
Nagelkerke R2 coefficient, estimated with a p value of 0.005
that 23% of the variation in the logistic regression model is
explained by the variables included in the model. This
proportion reflects a “median” influence of the covariates
investigated on the dependent variable as categorized by
Cohen (11). The cutoff values assuming a weak, median or
strong influence of covariates included in a regression model
are given as 2% to 15%, 16% to 35% and .35%, respec-
tively, in this reference.
As indicated in Table 4, of all the dependent variables
only serum levels of solubilized TNF-aRII and ICAM
remained statistically significant. Both variables contributed
equally to the goodness-of-fit of the model as indicated by
R values of partial correlation of 0.121 in both. Categorizing
serum levels of solubilized TNF-aRII and ICAM by tertiles
(cutoff values of tertiles were 2,977/3,619 ng/ml for sTNF-
aRII and 137/168 ng/ml for sICAM) revealed a 1.6- to
2.0-fold elevated relative risk attributable to both variables
as compared with the group belonging to the first tertile. No
obvious additive effects of both variables were observed (data
not shown).
DISCUSSION
In this study we focused on the role of several immunologic
variables that reflect distinct parts of the immunologic
system and their correlation with angiographically proven
CHD. Because the immunologic network presents an abun-
dance of positive and negative feedback mechanisms, infor-
mation obtained from different immunologic variables
might be highly redundant. A large number of growth
factors, cytokines and vasoregulatory molecules are known
to participate in atherogenesis (1).
Solubilized adhesion molecules and cytokine receptors
discriminate patients with CHD. Although leukocyte
count and CRP levels, as the two classic indicators of
inflammatory diseases, could discriminate patients with
CHD (12,13), these variables are obviously insensitive in a
cohort such as that investigated in our study. C-reactive
protein levels were relatively high as compared with those in
other studies (14). This might in part result from differences
in the methods used, because nephelometry, which was used
in our study, overestimates CRP levels in comparison to
approaches using enzyme-linked immunosorbent assay (15).
To our knowledge, this is the first study to investigate the
diagnostic value of solubilized adhesion molecules and
cytokine receptors for CHD in the same study group. As
confirmed by our study, significant differences between
patients with CHD and control subjects in serum levels of
these immunologic variables investigated were apparent
using univariate statistical procedures. In particular, we did
not find any differences between patients with and without
CABG. Therefore, it is unlikely that elevated levels of
circulating adhesion molecules and cytokine receptors in
patients with CHD in our study were caused by this
intervention.
Because subjects were not matched for age, differences in
the age distribution between groups were also expected.
However, as a limitation of this study, it has to be
mentioned that the selection criteria, including the setting
of the study, might have biased the age distribution of the
control group and diminished the validity of statements
Table 3. Comparison of Age and Serum Levels of Solubilized Adhesion Molecules and
Cytokine Receptors by Receiver-Operating Curve Analysis With Respect to the Presence of
Coronary Heart Disease
Area
Under the
Curve
Cutoff
Value
95%
Confidence
Interval
Age (yrs) 0.605 67 65–77
sIL-2 receptor (U/ml) 0.589 346 310–390
sTNF-aRII (pg/ml) 0.606 3,384 3,238–3,452
sVCAM (ng/ml) 0.557 647 640–669
sICAM (ng/ml) 0.553 154 144–158
sE-selectin (ng/ml) 0.580 46.9 42.5–49.4
See Table 2 for abbreviations.
Table 4. Multiple Logistic Regression Analysis of the
Association Between Age, Serum Levels of Solubilized
Adhesion Molecules and Cytokine Receptors and the Presence
of Coronary Heart Disease as an Independent Variable
R
Wald
Statistic
p
Value
Age 0.052 2.39 0.122
sIL-2 receptor 0.000 0.95 0.328
sTNF-aRII 0.121 4.16 0.041
sVCAM 0.000 0.55 0.457
sICAM 0.121 4.16 0.041
sE-selectin 0.000 1.13 0.288
See Table 2 for abbreviations.
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concerning an independent influence of age on the presence
of atherosclerotic lesions in coronary vessels.
The test accuracy of all variables was comparable, as
confirmed by ROC analysis (Table 3). In contrast, there
were no obvious differences in risk factors such as lipids,
which was partly owing to the treatment with lipid-lowering
drugs in the CHD group (Table 1). Data on the influence
of hepatic hydroxymethyl glutaryl coenzyme A (HMG-
CoA) reductase inhibitors on inflammatory processes are
rare. Fukuo et al. (16) did not observe an influence of
simvastatin on the cytokine production by human mono-
cytes and macrophages. Giroux et al. (17) reported a
diminished phagocytotic activity of human monocyte-
derived macrophages after in vitro treatment with simvasta-
tin. These observations provide some evidence that HMG-
CoA reductase inhibitors either do not influence the
inflammatory response at all or decrease it.
Role of solubilized adhesion molecules and cytokine
receptors in atherosclerosis. When introducing serum
levels of solubilized adhesion molecules, cytokine receptor
and age in a multivariate logistic regression model, only
solubilized TNF-aRII and ICAM remained significantly
correlated with the presence of CHD. This implies that
these variables are more independently related to the ap-
pearance of atherosclerosis than the other variables investi-
gated. TNF-aRII is expressed by many different cell types
(18). Its intracellular domain, in concert with TNF-aRI, is
proposed to be responsible for the signal transduction of
TNF-alpha (19). The proteolytic cleavage of the receptors
from the cell surface seems to be a downregulating mecha-
nism of the cell response to TNF-alpha (20). The solubi-
lized receptor is therefore closely related to TNF-alpha
levels. The capability of sTNF-aRII to independently
discriminate patients with CHD might derive from the
central role of monocytes and macrophages as a source of
TNF-alpha in all stages of atherogenesis (21). In contrast to
TNF-alpha, which has a very short half-life (22), the
solubilized receptor II shows stable basic serum levels (23)
and is therefore more suitable for laboratory investigations.
Solubilized IL-2 receptors have been extensively studied
in transplant atherosclerosis (24). The IL-2 receptor is
upregulated by IL-2, and its shedding is proposed to be a
regulatory means of IL-2 response (25). The presence of
CD251 T lymphocytes in atherosclerotic lesions supported
the theory of atherosclerosis as a chronic inflammatory
process (26), even though the association with serum levels
of the shedded receptor is unclear. In our study, however,
the significant differences between patients with CHD and
subjects without it were largely diminished by the other
variables of our study, as also observed for sVCAM and
sE-selectin. Elevated serum levels of IL-2 receptor were also
observed in patients with dilated cardiomyopathy and cor-
related positively with New York Heart Association func-
tional class (27). This observation was also suggestively seen
in the other adhesion molecule and cytokine receptor levels
investigated and fits well with current concepts on the
pathogenesis of the clinical syndrome of heart failure (28).
Although there are many pathophysiologic connections
between adhesion molecules and atherogenesis (1,29), there
are still conflicting results reported with regard to the
discriminative value of distinct solubilized adhesion mole-
cules (2–4). In our collective, only sICAM was indepen-
dently related to the presence of atherosclerosis in a multi-
variate model including age and serum levels of three
adhesion molecules and two cytokine receptors. Most of the
other studies did not use multivariate analysis to confirm the
independent correlation of these variables to atherosclerosis.
In our study E-selectin and VCAM serum levels seem to be
obviously affected by the other covariates. Morisaki et al. (2)
also showed that sICAM is related to atherosclerosis inde-
pendent of sVCAM in a multivariate analysis. However,
neither their study nor our own can solve the question of
causality regarding atherosclerosis. It also has to be stated
that although sICAM and TNF-aRII levels emerged as
two independent discriminators for the presence of athero-
sclerotic lesions in coronary arteries, in our study the
pathophysiologic background of the absence of an expected
additive effect of both variables remains unclear and must be
further elucidated.
Conclusions. The present results indicate that both circu-
lating ICAM and TNF-aRII should be further evaluated as
two potential sensitive immunologic markers for atheroscle-
rotic changes in the coronary system.
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